E2 Concludes ENGULF Trial Enrollment for Innovative PE Treatment
Pivotal trial evaluates safety and efficacy of the H?lo™ PE Thrombectomy System for the removal of blood clots from the lungs
E2 (Endovascular Engineering, Inc.), a pioneering medical device company, proudly announces the completion of patient enrollment in the ENGULF Investigational Device Exemption (IDE) study's pivotal cohort. This trial focuses on the H?lo™ PE Thrombectomy System, a groundbreaking approach to treating pulmonary embolism (PE), a severe condition resulting from blood clots blocking pulmonary arteries.
Dr. Andrew Klein, the ENGULF National Principal Investigator from Piedmont Hospital, expressed enthusiasm for the trial's progress. He noted, "The ENGULF trial represents an impressive journey of innovation during which E2 and investigators were able to introduce and evaluate several new technologies within the trial. This period marks exciting advancements in the use of mechanical thrombectomy to treat our patients suffering from this life-threatening condition."
The ENGULF study, identified under NCT05597891, took place at 19 leading interventional cardiology, radiology, and vascular surgery centers across the United States. It follows the successful publication of the feasibility cohort, emphasizing the clinical viability of the H?lo PE Thrombectomy System.
Dr. Julie Bulman, Co-Principal Investigator from Beth Israel Deaconess Medical Center, highlighted the exceptional collaboration among ENGULF investigators. She stated, "The rapid enrollment level and teamwork among the ENGULF investigators were remarkable, showing the excitement about evaluating new technologies for PE treatments like the H?lo System. We eagerly anticipate reporting the trial outcomes soon and contributing further to the critical body of evidence for PE treatment."
The H?lo PE Thrombectomy System is a significant advancement in clot removal technology. It is designed with a patented dual-action mechanism that combines effective aspiration with advanced clot disruption capabilities. This innovative system incorporates Flow Mitigation Technology™, which enables clinicians to remove clots while significantly minimizing blood loss—a crucial aspect in treating patients suffering from pulmonary embolism.
According to Dan Rose, CEO of E2, the collaborative efforts of their physician partners and volunteer patients have been vital in the trial's progression. He shared, "Our collective goal is to enhance the treatment of PE. We believe that the H?lo System offers distinct advantages over the current standard practices, and we are now one significant step closer to having this lifesaving technology accessible to patients across the United States."
Pulmonary embolism remains a leading cause of cardiovascular-related mortality and morbidity. Current treatment options often present a challenging balance between efficacy and safety. The ENGULF study aims to demonstrate that the H?lo Thrombectomy System can provide a solution that effectively addresses both concerns.
E2 extends heartfelt gratitude to its clinical partners, investigators, and strategic investors for their unwavering support. The company looks forward to sharing the outcomes of this groundbreaking study and continuing its commitment to redefine interventions for pulmonary embolism.
About Endovascular Engineering, Inc.
Endovascular Engineering, Inc. ("E2") stands at the forefront of revolutionizing venous thromboembolism (VTE) treatment. As a venture-backed innovator within the medical technology sector, E2 is focused on delivering transformative solutions that elevate the standard of care concerning clot removal. The technology platform represents the intersection of clinical insights alongside engineering expertise, designed to tackle the intricate challenges associated with VTE interventions.
Caution: The H?lo PE Thrombectomy System is classified as an investigational device, limited by federal law to investigational use.
For further details, please reach out and follow us on LinkedIn @EndovascularEngineering.
Additional information regarding the trial (NCT05597891), including eligibility and clinical trial sites, is available through clinical trial registries.
Frequently Asked Questions
What is the main focus of the ENGULF study?
The ENGULF study aims to evaluate the safety and efficacy of the H?lo™ PE Thrombectomy System for treating pulmonary embolism.
What advancements does the H?lo PE Thrombectomy System offer?
This system features a patented dual-action mechanism that combines aspiration and clot disruption while minimizing blood loss.
Who are the principal investigators involved in the trial?
Dr. Andrew Klein and Dr. Julie Bulman are serving as the principal investigators for the ENGULF trial.
How does E2 contribute to innovation in medical technology?
E2 invests in developing cutting-edge solutions that revolutionize existing treatments in venous thromboembolism.
How does the H?lo System improve patient outcomes?
The H?lo System aims to effectively address the balance between treatment efficacy and safety for patients with pulmonary embolism.
